The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Organizing pneumonia pattern (an area or areas of consolidation on imaging)
BOOP cases diagnosed solely on imaging (e.g. PMID 21761513) are not generally recorded here, as BOOP can be diagnosed solely on pathology. The role of the drug vs. that of the underlying bowel disease must be critically evaluated in every individual patient (PMID 24461446, 42719527).
Publications
Mesalazine-related lung disease in a patient with ulcerative colitis: A case report.
Medicine. 2018;97(48):e13242
[Organizing pneumonia during treatment with mesalazine].
Revue des maladies respiratoires. 2014;31(1):70-7
Acute eosinophilic pneumonia related to a mesalazine suppository.
Asia Pacific allergy. 2013;3(2):136-9
Mesalazine-induced bronchiolitis obliterans organizing pneumonia (BOOP) in a patient with ulcerative colitis and primary sclerosing cholangitis.
Inflammatory bowel diseases. 2011;17(10):E137-8
The lung in inflammatory bowel disease.
Medicine. 1993;72(3):151-83